cyc 682 has been researched along with at 13387 in 1 studies
| Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (at 13387) | Trials (at 13387) | Recent Studies (post-2010) (at 13387) |
|---|---|---|---|---|---|
| 30 | 5 | 18 | 59 | 4 | 57 |
| Protein | Taxonomy | cyc 682 (IC50) | at 13387 (IC50) |
|---|---|---|---|
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.0437 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.138 | |
| Endoplasmin | Homo sapiens (human) | 0.022 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.013 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byrd, JC; Lai, TH; Lapalombella, R; Liu, C; Mims, A; Mitchell, S; Orwick, S; Plunkett, W; Puduvalli, VK; Ravikrishnan, J; Sampath, D; Woyach, J; Wu, PJ | 1 |
1 other study(ies) available for cyc 682 and at 13387
| Article | Year |
|---|---|
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzamides; Cell Line, Tumor; Cytosine; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Leukemia, Myeloid, Acute | 2019 |